Key result
In a porcine model of myocardial infarction, 7-day intravenous infusion of rhPDGF-AB improved survival by 40% and left ventricular ejection fraction by 11.5% at 1 month compared with vehicle.
Why the study?
Targeting scar formation after MI may prevent heart failure or death from ventricular arrhythmias, and clinical translation required testing rhPDGF-AB in a clinically relevant porcine ischemia-reperfusion model.
Does 7-day intravenous infusion of rhPDGF-AB improve survival and cardiac function in a porcine model of myocardial ischemia-reperfusion?
RCT (n=36)
randomized
Does 7-day intravenous infusion of rhPDGF-AB improve survival and cardiac function in a porcine model of myocardial ischemia-reperfusion?
In a porcine model of myocardial infarction, rhPDGF-AB improved survival, cardiac function, and scar mechanics, suggesting strong translational potential for post-MI therapy.
No takes yet. Share an insight, caveat, or question.
Does not alter post-MI care; leaves open whether porcine benefits of rhPDGF-AB translate to patients.
Thavapalachandran et al. (2020) conducted an RCT in myocardial infarction (n=36). recombinant human platelet-derived growth factor-AB (rhPDGF-AB) vs. vehicle was evaluated on survival and left ventricular ejection fraction. In a porcine model of myocardial infarction, 7-day intravenous infusion of rhPDGF-AB improved survival by 40% and left ventricular ejection fraction by 11.5% at 1 month compared with vehicle.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: